Healthcare 

Guggenheim Securities continues to provide healthcare clients with independent insight and expertise across the biopharma, medical devices, and healthcare services sectors. Our full-service firm includes a leading healthcare investment banking franchise, trusted as a long-term, strategic advisor, as well as sales & trading services and a research department that performs deep primary research and generates actionable ideas.

The Century Project: Living Longer, but Less Healthy

Representative Transactions in Healthcare

Social Media

What Top Dealmakers Expect to See This Year in Health-Care M&A

LinkedIn: Bloomberg

What Top Dealmakers Expect to See This Year in Health-Care M&A

Senior Managing Directors Punit Mehta and David Blais shared their views on the M&A outlook in healthcare with Michelle Davis from Bloomberg News.

Read More

Guggenheim Congratulates Summit Health-CityMD

LinkedIn: Summit City Health

Guggenheim Congratulates Summit Health-CityMD

Guggenheim Securities, LLC congratulates Summit Health-CityMD, a portfolio company of Warburg Pincus LLC, in connection with its definitive agreement to be acquired by VillageMD, an affiliate of Walgreens Boots Alliance. Guggenheim served as a financial advisor to Summit Health-CityMD on the transaction.

Read More

Guggenheim’s Seamus Fernandez Offers His Bullish Case for Merck

LinkedIn: CNBC Closing Bell: Overtime

Guggenheim’s Seamus Fernandez Offers His Bullish Case for Merck

Biopharmaceutical Analyst Seamus Fernandez provides insight on CNBC Closing Bell: Overtime into his recent report on MRK.

Read More

Guggenheim Thanks Attendees of Immunology and Neurology Conference

LinkedIn: Immunology and Neurology Conference

Guggenheim Thanks Attendees of Immunology and Neurology Conference

Guggenheim Securities would like to thank the presenters and attendees of this week’s Immunology and Neurology Conference.

Read More

Guggenheim Thanks Attendees of Therapeutics Conference

LinkedIn: Therapeutics Conference

Guggenheim Thanks Attendees of Therapeutics Conference

Guggenheim Securities would like to thank the participants and attendees of this week’s Therapeutics Conference.

Read More

I&I Spotlight Series - Treg-based Therapies

LinkedIn: I&I Spotlight Series

I&I Spotlight Series - Treg-based Therapies

Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja, covering the biotechnology sector, on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.

Read More

I&I Spotlight Series: Treg-Based Therapies

LinkedIn: Treg-Based Therapies

I&I Spotlight Series: Treg-Based Therapies

Senior Healthcare Sales Specialist Whitney Wolfe interviews Biotechnology Research Analyst Yatin Suneja, covering the biotechnology sector, on the rapid innovation of Tregs for the treatment of autoimmune diseases and diseases of the nervous system.

Read More

Guggenheim Thanks Attendees of I&I Spotlight Series

LinkedIn: I&I Spotlight Series

Guggenheim Thanks Attendees of I&I Spotlight Series

Thank you to everyone who attended this week’s Guggenheim I&I Spotlight Series on Treg-based Therapies.

Read More

Guggenheim Thanks Attendees of Radiopharmaceutical Day

LinkedIn: Radiopharmaceutical Day

Guggenheim Thanks Attendees of Radiopharmaceutical Day

Guggenheim would like to thank the participants and attendees of Tuesday's Radiopharmaceutical Day.

Read More

Guggenheim Thanks Attendees of Synthetic Lethality Day

LinkedIn: Synthetic Lethality Day

Guggenheim Thanks Attendees of Synthetic Lethality Day

Thank you to everyone that attended Monday's virtual Guggenheim Healthcare Talk for Synthetic Lethality Day.

Read More

Tech-Enabled Care Industry Overview

LinkedIn: Tech-Enabled Care

Tech-Enabled Care Industry Overview

Director of Research Craig Peckham interviews Senior Managing Director Sandy Draper and Vice President Jack Wallace, both Equity Research Analysts covering the Healthcare IT & Services sector, on their views on digital healthcare.

Read More

Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day

LinkedIn: Genomic Medicines and Rare Disease Day

Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day

At Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day, we provided healthcare clients with access to industry leadership in the constantly evolving sector.

Read More

Highlights From the Second Guggenheim Targeted Protein Degradation Day

LinkedIn: Targeted Protein Degradation Day

Highlights From the Second Guggenheim Targeted Protein Degradation Day

Equity Research Analyst Michael Schmidt, who covers biotech, provides highlights from our Targeted Protein Degradation Day, a part of the Guggenheim Healthcare Talks series, on March 16.

Read More

Guggenheim Thanks Oncology Conference Attendees

LinkedIn: Oncology Conference

Guggenheim Thanks Oncology Conference Attendees

At this year’s Oncology Conference, we provided clients with direct access to industry leadership teams in a complex and constantly evolving sector.

Read More

Guggenheim Securities Healthcare - Biopharma Perspectives

LinkedIn: Biopharma Perspectives

Guggenheim Securities Healthcare - Biopharma Perspectives

At Guggenheim Securities, LLC we provide biopharmaceutical clients with independent insight and advice. As we survey 2022, we are sharing summaries of some of our most compelling thematic reports from the past year.

Read More

To access more information related to Healthcare at Guggenheim Securities, contact GSInfo@guggenheimpartners.com.


Important Notices and Disclosures

The information and materials referenced herein (together, the “materials”) are presented for informational and educational purposes only and should not be considered a recommendation of any particular security, strategy or investment product, as investing advice of any kind, or as offering or providing any investment product or service. The materials are not a product of the research department of Guggenheim Securities, LLC or any of its affiliates’ (“Guggenheim”) and should not be construed as a research report, recommendation or advice, or an offer or solicitation with respect to the purchase or sale of any investment. The materials are not provided in an advisory or fiduciary capacity and may not be relied upon for or in connection with the making of investment decisions. The views expressed herein are solely those of the authors and may differ from the views of other officers, directors, employees or other representatives (as to any person or entity, its “Representatives”) of Guggenheim. The authors’ opinions are subject to change without notice. Sources for the information contained herein are believed to be reliable, but the information is not guaranteed as to, and Guggenheim and its Representatives make no representation or warranty regarding, accuracy or completeness of any information contained herein or otherwise. Guggenheim may have a business relationship with certain issuers mentioned herein, or may otherwise underwrite, hold a position, buy or sell as principal in the securities of any issuer mentioned. Guggenheim may have in the past provided, may currently be providing and may in the future seek to provide investment banking, financial advisory and other services to, and have other material relationships with, the issuers of securities, loans and other financial instruments referred to herein and their affiliates. With respect to any position Guggenheim may hold, Guggenheim may have interests different from or adverse to your interests. No part of these materials may be reproduced in any form, or referred to in any other publication, without express written permission of Guggenheim. The materials have been prepared and submitted as of the relevant dates referenced herein, reflect information available to Guggenheim as of or prior to such dates and are based on economic, capital markets and other conditions as of or prior to such dates. There is neither representation nor warranty as to the current accuracy of, nor liability for, decisions based on these materials and information. Guggenheim assumes no obligation or liability (express or implied) for updating, correcting or otherwise revising the materials. By accepting delivery of this material, each recipient will be deemed to acknowledge and agree to the matters set forth above.


Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer. All rights reserved.